Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Taylor

Showing results (281-290 of 316) with videos related to

Pageof 32
Sort By:
BMJ Simulation & Technology Enhanced Learning|May 6, 2022
Simulation capacity building in rural Indian hospitals: a 1-year follow-up qualitative analysisVeena Sheshadri, Isaac Wasserman, Alexander W Peters, et al.
Molecular Carcinogenesis|May 2, 2024
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltrationAlice N Weaver, Wade T Iams, Jong Chul Park, et al.
Journal for Immunotherapy of Cancer|March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsAung Naing, Justin F Gainor, Hans Gelderblom, et al.
Biorxiv : the Preprint Server for Biology|February 13, 2023
Single-cell RNA sequencing reveals dysregulated fibroblast subclusters in prurigo nodularisJay R Patel, Marina Z Joel, Kevin K Lee, et al.
JCO Oncology Practice|June 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 TherapyMegan Othus, Thach-Giao Truong, Elad Sharon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2019
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortNeal E Ready, Patrick A Ott, Matthew D Hellmann, et al.
The New England Journal of Medicine|April 21, 2015
Nivolumab and ipilimumab versus ipilimumab in untreated melanomaMichael A Postow, Jason Chesney, Anna C Pavlick, et al.
Open Heart|November 28, 2017
Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathyJennifer E Ho, Ling Shi, Sharlene M Day, et al.
JAMA Cardiology|February 28, 2017
The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet StudyCarolyn Y Ho, Sharlene M Day, Steven D Colan, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|September 22, 2018
The Emergency Medicine Specimen Bank: An Innovative Approach To Biobanking In Acute CareJessica L Saben, Shelby K Shelton, Andrew J Hopkinson, et al.
Pageof 32

Showing results (281-290 of 316) with videos related to

Sort By:
Pageof 32
BMJ Simulation & Technology Enhanced Learning|May 6, 2022
Simulation capacity building in rural Indian hospitals: a 1-year follow-up qualitative analysisVeena Sheshadri, Isaac Wasserman, Alexander W Peters, et al.
Molecular Carcinogenesis|May 2, 2024
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltrationAlice N Weaver, Wade T Iams, Jong Chul Park, et al.
Journal for Immunotherapy of Cancer|March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsAung Naing, Justin F Gainor, Hans Gelderblom, et al.
Biorxiv : the Preprint Server for Biology|February 13, 2023
Single-cell RNA sequencing reveals dysregulated fibroblast subclusters in prurigo nodularisJay R Patel, Marina Z Joel, Kevin K Lee, et al.
JCO Oncology Practice|June 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 TherapyMegan Othus, Thach-Giao Truong, Elad Sharon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2019
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortNeal E Ready, Patrick A Ott, Matthew D Hellmann, et al.
The New England Journal of Medicine|April 21, 2015
Nivolumab and ipilimumab versus ipilimumab in untreated melanomaMichael A Postow, Jason Chesney, Anna C Pavlick, et al.
Open Heart|November 28, 2017
Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathyJennifer E Ho, Ling Shi, Sharlene M Day, et al.
JAMA Cardiology|February 28, 2017
The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet StudyCarolyn Y Ho, Sharlene M Day, Steven D Colan, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|September 22, 2018
The Emergency Medicine Specimen Bank: An Innovative Approach To Biobanking In Acute CareJessica L Saben, Shelby K Shelton, Andrew J Hopkinson, et al.
Pageof 32